ClinicalTrials.gg
CompletedNCT00099749Updated Feb 23, 2017

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

A Phase 2/3 interventional study of FTY 720 in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Kidney, immunosuppression, transplant, rejection
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female
  • Between 18 to 65 years old

Exclusion criteria

Exclusion Criteria:

  • Patients in need of multiple organ transplants
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
255 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Biopsy-proven acute rejection (BPAR), graft loss, death and study discontinuation, within 6 months post transplantation.

Secondary outcomes

  1. Safety/tolerability based on adverse event reporting.

  2. BPAR, graft loss, death and study discontinuation, within 6 and 12 months post transplantation.

  3. Efficacy parameters between the 3 treatment groups within 6 and 12 months post-transplantation.

07

Study locations

5 sites
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • SIU School of Medicine
    Springfield, Illinois 62781, United States
  • St. Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
08

References and documents

Publications

  • Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P; FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007 Oct 15;84(7):885-92. doi: 10.1097/01.tp.0000281385.26500.3b. PubMed 17984842 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003 and a primary completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2004
First posted
Dec 20, 2004
Start
Nov 2003
Primary completionActual
Apr 2006
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00099749
Responsible party
Sponsor
First posted
Dec 20, 2004
Start date
Nov 2003
Primary completion
Apr 2006
Last update
Feb 23, 2017

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion